All Vaccinology articles – Page 29
-
NewsResearchers develop world’s first mRNA vaccine for deadly bacteria
A team of researchers has developed an mRNA-based vaccine that is 100% effective against a type of bacteria that is lethal to humans.
-
NewsClinical trial finds temperature-stable TB vaccine is safe and prompts immune response
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.
-
NewsHIV vaccine candidate aims to block virus before it takes root
The National Institutes of Health has awarded $3.8 million to Texas Biomedical Research Institute to further develop a promising HIV vaccine candidate that stops the virus upon entry, before it begins rapidly spreading throughout the body.
-
NewsNew inoculation based on Ebola VSV vaccine concept protects macaques
Researchers have successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.
-
NewsNew vaccine targets life-threatening fungal infections
A new vaccine from the University of Georgia could be the first clinically approved immunization to protect against invasive fungal infections, a growing concern as antifungal drug resistance increases.
-
NewsUS approves world’s first vaccine to protect honey bees
The world’s first vaccine for honey bees has been approved by authorities in the US.
-
NewsPhase 2 trial of Ebola vaccines yields promising results
An international team of scientists has published the results of a large-scale randomized clinical trial in West Africa which confirms the safety of three vaccine regimens for Ebola and suggests an immune response is induced and maintained for up to 12 months.
-
-
NewsVaccine for Lyme disease one step closer with promising six-month results
A vaccine for Lyme disease is one step closer after Pfizer Inc and Valneva SE reported positive results in their antibody persistence data six months after completing a three-dose or two-dose schdule in children and adults with vaccine candidate VLA15.
-
NewsKenneth Timmis wins prestigious award for achievements in microbiology
The 2023 FEMS-Lwoff Award for Achievements in Microbiology has been awarded to Professor Kenneth Timmis, former Editor-in-Chief of AMI journals Environmental Microbiology, Environmental Microbiology Reports and Microbial Biotechnology.
-
NewsClover’s vaccine candidate reduced household transmission of SARS-CoV-2
A collaboration between Clover Biopharmaceuticals Ltd and the International Vaccine Institute showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebos.
-
NewsBiovac signs deal with IVI to deliver oral cholera vaccine for African and global markets
South African based Bio-pharmaceutical company Biovac has concluded a ground-breaking licensing and technology transfer agreement with the International Vaccine Institute (IVI), a non-profit international organisation headquartered in South Korea, for the manufacture of an oral cholera vaccine (OCV).
-
NewsHidden Nsp1 cavity means Covid’s Spike protein is no longer the only target
Researchers have revealed the existence of a hidden ’’pocket’ on the surface of the non-structural protein Nsp1 on the surface of the Covid-19 virus which could offer a potential drug target and alternative to the Spike protein targeted by vaccines.
-
NewsIntranasal COVID vaccine works against variants in animals
Researchers have developed an intranasal vaccine against Covid-19 that can fight off the original virus and two variants in hamsters.
-
NewsNew immersive nanovaccine tackles Flavobacterium diseases in fish without injection
Researchers from the Faculty of Veterinary Science at Chulalongkorn University in Thailand have developed a nanovaccine to prevent bacterial gill diseases in freshwater fish species such as Tilapia and freshwater Asian sea bass.
-
NewsmRNA vaccines significantly reduce severity of Delta, Omicron COVID-19 infections
People who have received several doses of an mRNA COVID-19 vaccine are more likely to have milder illnesses if infected with Delta or Omicron variants than those who are unvaccinated.
-
FeaturesBlue plaque microbiology
Marking sites associated with notable people or events is an estimable and widespread practice.
-
FeaturesParental decisions about vaccination: a paediatrician’s perspective
Vaccine hesitancy is a relatively new term for a phenomenon that is as old as vaccination itself
-
FeaturesMitigate or suppress—coming to grips with the COVID-19 pandemic
In the absence of an efficient vaccine, the control of the COVID-19 pandemic currently relies on non-pharmaceutical interventions.
-
FeaturesAssuring the safety of vaccines
A vaccine undergoes a comprehensive regime of testing, and its use is subject to continuous vigilance throughout its lifecycle to ensure safety, efficacy and quality.